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Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the
phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation
by protein kinase C
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*Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K., and †Institute of
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We have previously identified the PKC (protein kinase C)-
anchoring protein RACK1 (receptor for activated C-kinase 1), as a
specific binding partner for the cAMP-specific phosphodiesterase
PDE4D5, suggesting a potential site for cross-talk between
the PKC and cAMP signalling pathways. In the present
study we found that elevation of intracellular cAMP, with
the β2-adrenoceptor agonist isoproterenol (isoprenaline), led to
activation of PDE4 enzymes in the particulate and soluble
fractions of HEK (human embryonic kidney)-293 cells. In contrast
activation of PDE4D5, with isoproterenol and the PKC activator
PMA, was restricted to the particulate fraction, where it interacts
with RACK1; however, RACK1 is dispensable for anchoring
PDE4D5 to the particulate fraction. Kinetic studies demonstrated
that RACK1 alters the conformation of particulate-associated
PDE4D5 so that it more readily interacts with its substrate cAMP
and with rolipram, a PDE4 inhibitor that specifically targets
the active site of the enzyme. Interaction with RACK1 was
also essential for PKC-dependent and ERK (extracellular-signal-
regulated kinase)-independent phosphorylation (on Ser126), and
activation of PDE4D5 in response to PMA and isoproterenol, both
of which trigger the recruitment of PKCα to RACK1. Together
these results reveal novel signalling cross-talk, whereby RACK1
mediates PKC-dependent activation of PDE4D5 in the particulate
fraction of HEK-293 cells in response to elevations in intracellular
cAMP.
Key words: cAMP, intracellular targeting, phosphodiesterase
(PDE), protein kinase C (PKC), receptor for activated C-kinase 1
(RACK1).
INTRODUCTION
cAMP is a ubiquitous second messenger that controls pleiotropic
cellular actions through the direct activation of its effectors,
PKA (proteins kinase A) and EPAC (exchange protein activated
by cAMP) [1,2]. cAMP PDEs (phosphodiesterases) are crucial
components of the cAMP signalling system and represent the only
means of decreasing cAMP levels in cells, through hydrolysis
to 5′-AMP [3]. Of the 11 known classes of cyclic nucleotide
PDEs, eight are able to hydrolyse cAMP [4,5]. Of these the
PDE4 cAMP-specific class is widely expressed in a variety
of tissues and accounts for the majority of cAMP hydrolysis
activity in cells [6]. PDE4s are encoded by four genes that,
through complex alternative splicing of cognate mRNAs, give
rise to approx. 20 PDE subgroups, termed A−D [6]. Each PDE4
subgroup has a unique C-terminus and alternative splicing at
the N-terminus results in a unique N-terminal region for each
of the PDE4 classes, which is thought to influence stability,
enzyme activity and intracellular targeting [6,7]. For example,
the PDE4D group is distinguishable by unique N-terminal regions
that have been found to readily interact with other cellular proteins
[6]; phosphodiesterase PDE4D5 has been found to interact with
the ubiquitously expressed WD-repeat signalling scaffold protein
RACK1 (receptor for activated C-kinase 1) [8,9], although to date
the precise function of this signalling complex is largely unknown.
RACK1 has been found to act as both anchor and shuttle for a
number of cellular proteins, including conventional PKC (protein
kinase C) isoforms, dynamin-1, Ras-GAP (GTPase-activating
protein), Src and several integrin receptors, as well as a variety
of viral proteins [8]. It has been suggested that RACK1 recruits
these proteins to their appropriate subcellular locations thereby
integrating their actions into intracellular signalling pathways
[8]. This raises the question as to whether RACK1 affects the
intracellular targeting and activity of PDE4D5 in a similar manner.
The interaction between PDE4D5 and RACK1 is highly specific
since, to date, RACK1 has not been shown to bind to any
other members of the cAMP-specific PDE4 family, nor does
PDE4D5 bind to other WD-repeat proteins [9]. RACK1 and
PDE4D5 are believed to interact in a manner similar to the
heterotrimeric G-protein subunits, Gβ and Gγ [8] in that blades of
the RACK1 β-propeller form a groove to which the N-terminus
of PDE4D5 binds [8]. An 88-amino-acid subdomain, termed the
RAID1 (RACK1-interaction domain), located in the N-terminal
region of PDE4D5 was identified as an essential requirement
for RACK1 binding [10]. In addition, a low-affinity RACK1-
binding site has also been located in the PDE4D5 catalytic
domain [11]. Further studies have shown that although PDE4D5
appears to be only able to bind one protein at a time [11], it
is likely that RACK1 has the facility to bind multiple proteins
simultaneously, e.g. migration of breast cancer cells in response
to IGF (insulin-like growth factor)-1 is thought to be regulated
by a RACK1-directed protein complex involving the IGF-1
Abbreviations used: β2-AR, β2-adrenoreceptor; CREB, cAMP-response-element-binding protein; DMEM, Dulbecco’s modified Eagle’s medium; DOTAP,
dioleoyltrimethylammonium propane; ECL, enhanced chemiluminescence; ERK, extracellular-signal-regulated kinase; GFX, GF109203X; GST, glutathione
transferase; HEK, human embryonic kidney; HRP, horseradish peroxidase; IGF, insulin-like growth factor; MEK, MAPK (mitogen-activated protein
kinase)/ERK kinase; PDE, phosphodiesterase; PKA, protein kinase A; PKC, protein kinase C; PP2A, protein phosphatase 2A; RACK1, receptor for
activated C-kinase 1; TBST, Tris-buffered saline containing 0.1% Tween 20; VSV, vesicular stomatitis virus.
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receptor, integrin receptors and FAK (focal adhesion kinase)
[12]. This ability of RACK1 raises questions as to whether
additional proteins binding to RACK1 can influence the function
and specificity of the complex with regard to the intracellular
targeting, conformation and activity of RACK1-bound PDE4D5.
In support of this it has been shown that interaction with RACK1
in vitro increases the sensitivity of PDE4D5 to the PDE4-selective
inhibitor rolipram {4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-
pyrrolidinone}, which suggests that RACK1 may have some
influence on the conformation of bound PDE4D5 [9]. Moreover,
the influence of additional RACK1-binding partners on the status
of PDE4D5, such as conventional PKC isoforms, e.g. cAMP-
activatable PKCα [13], is largely unknown and may reveal key
areas of novel signalling regulation and cross-talk. The aims of
the present study are therefore to determine the consequences
of interaction with RACK1 on the regulation of PDE4D5.
MATERIALS AND METHODS
Materials
GFX (GF109203X), PMA, Ro31-7549, rolipram and isoproter-
enol (isoprenaline) were purchased from Merck Biosciences.
Antibodies against GAPDH (glyceraldehyde-3-phosphate de-
hydrogenase), PKCα, RACK1 (IgM clone) and the VSV
(vesicular stomatitis virus) epitope were purchased from Ambion,
Cell Signalling Technology, BD Transduction Laboratories and
Sigma−Aldrich respectively. Human wild-type PDE4D5 and
PDE4D5-L33D cDNAs [11], both with a C-terminal VSV
tag were generously provided by Professor Miles D. Houslay
(University of Glasgow, Scotland, U.K.)
Cell culture
HEK (human embryonic kidney)-293 cells were cultured at
37 ◦C under a 5% (v/v) CO2 atmosphere in DMEM (Dulbecco’s
modified Eagle’s medium; Sigma−Aldrich) containing 10%
(v/v) fetal bovine serum (Sigma–Aldrich), 2 mM L-glutamine and
2% (w/v) penicillin/streptomycin.
Transfection of cells
Cells were transfected at approx. 50% confluence with a DOTAP
(dioleoyltrimethylammonium propane) methyl sulfate/DNA
mixture, prepared by diluting 7.5 μg of plasmid DNA 1:10 (v/v)
in DMEM then mixing with DOTAP methyl sulfate diluted in
DMEM according to the manufacturer’s instructions. The mixture
was then incubated at room temperature (18 ◦C) for 30 min before
being added to cells in fresh culture medium. Cells were then
incubated overnight at 37 ◦C under a 5% (v/v) CO2 atmosphere
before being used in experiments.
High-speed cell fractionation
To obtain membrane pellet and soluble fractions, cells were
treated with pharmacological agents, harvested into lysis buffer
[10 mM Tris/HCl, pH 7.5, 0.1 mM EDTA and protease inhibitor
cocktail (Boehringer)] and then lysed by seven strokes of a 26.5
gauge needle fixed to a 1-ml disposable syringe. Unbroken cells
and nuclei were pelleted in a bench-top centrifuge at 1000 g for
5 min at 4 ◦C. Supernatants were then transferred into chilled
Beckman ultracentrifuge tubes and then centrifuged in a bench-
top ultrafuge at 75000 rev./min in a TLA-110 rotor for 30 min at
4 ◦C. The supernatant fraction was retained and stored at −80 ◦C
for future use. The pellet fraction was resuspended in 500 μl of
lysis buffer and centrifuged as above for a further 30 min. The
resulting supernatant was discarded and the membrane fraction
resuspended in lysis buffer and stored at −80 ◦C for future use.
Purification of recombinant PDE4D5
Bacteria expressing pGEX-5X-3 containing a cDNA for wild-
type PDE4D5 were grown to a D600 of 0.6 and then induced
with 1.0 mM isopropyl β-D-thiogalactopyranoside (Roche) and
grown for a further 4 h at 30 ◦C. Bacteria were then harvested
by centrifugation at 4000 g for 10 min at 4 ◦C and the bacterial
pellets frozen at −80 ◦C overnight. To purify recombinant GST
(glutathione transferase)−PDE4D5, pellets were resuspended in
10 ml of ice-cold resuspension buffer (50 mM Tris/HCl, pH 8.0,
100 mM NaCl, 1 mM EDTA, 10 mM 2-mercaptoethanol and
complete protease inhibitor mixture) and sonicated on a maximal
setting for 4× 30 s on ice. Triton X-100 was then added to
a final concentration of 0.02%, and cell debris was removed
by centrifugation at 10000 g for 10 min at 4 ◦C. The cleared
lysate was then incubated with a 1/10 volume of pre-equilibrated
glutathione−Sepharose beads (Pharmacia) for 1 h with end-
over-end turning at 4 ◦C. The beads were then collected by
centrifugation at 2000 g for 1 min and washed three times with
resuspension buffer. The fusion proteins were eluted by the
addition of 10 mM glutathione in 50 mM Tris/HCl, pH 8.0. The
fusion proteins were dialysed three times against 50 mM Tris/HCl,
pH 8.0, 100 mM NaCl and 5% (v/v) glycerol, then stored at
−80 ◦C until required.
Co-immunoprecipitation experiments
Equal amounts of cell pellet (crude membrane) or supernatant
(cytosol) protein were prepared in equal amounts of lysis buffer.
Following this 0.1% Triton X-100 was added to each sample
which were then incubated on ice for 15 min. At this stage
a 50 μl aliquot of each sample was retained and boiled in
Laemmli electrophoresis buffer [14] as input controls. Samples
were pre-cleared by adding 5 μg of mouse IgM and 50 μl of
anti-(mouse IgM) antibody−agarose (Sigma−Aldrich) to each
sample. Samples were then incubated on an orbital shaker
for 30 min at 4 ◦C. Beads were then pelleted (13000 g for
0.5 min) and the supernatant transferred to fresh Eppendorf
tubes. Duplicates of each sample were then treated with either
5 μg of anti-RACK1 antibody (IgM clone) or 5 μg of mouse
IgM and incubated on a wheel in a cold room for 30 min.
A total of 50 μl of anti-(mouse IgM) antibody−agarose was
then added to each Eppendorf tube and the samples were in-
cubated at 4 ◦C for a further 30 min. The agarose beads were then
pelleted for 30 s at 13000 g and washed three times with 500 μl
of lysis buffer. Beads were then boiled in electrophoresis buffer
and separated by SDS/PAGE (12% gels) along with the retained
input controls.
Western immunoblotting
Cells were scraped directly into Laemmli electrophoresis buffer
[14] and separated by SDS/PAGE (12% gels) before being
transferred on to nitrocellulose membranes. Membranes were
either blocked in 5% (w/v) dried milk powder in TBST (Tris-
buffered saline containing 0.1% Tween 20) or 5% (w/v) BSA
in TBST for phospho-specific antibodies. Membranes were then
incubated overnight with the appropriate primary antibody at
4 ◦C. Primary antibody was then removed and membranes were
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washed three times with TBST and were then incubated for
1 h at room temperature with HRP (horseradish peroxidase)-
conjugated secondary antibody. Blots were developed using ECL
(enhanced chemiluminescence; GE Healthcare) according to the
manufacturer’s instructions.
Peptide array experiments
RACK1 peptide arrays were produced by automatic SPOT
synthesis [15] and were synthesized on continuous cellulose
membrane supports on Whatman 50 cellulose membranes
using Fmoc (fluoren-9-ylmethoxycarbonyl)-chemistry with an
AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments
AG) [15,16]. The interaction of spotted peptides with
GST−PDE4D5 fusion protein was determined by overlaying the
cellulose membranes with 10 μg/ml recombinant protein. Bound
recombinant GST−PDE4D5 was detected with specific rabbit
antisera and secondary anti-rabbit HRP-coupled antibody (1:2500
dilution; Dianova), and was visualized by ECL (as above).
PDE enzyme assay
PDE activity in samples was assayed in cell extracts as
described previously [4], using a 0.2 μM cAMP substrate
solution containing 5 μCi [3H]cAMP per ml prepared in assay
buffer (40 mM Tris/HCl, pH 7.4, 5 mM MgCl2 and 3.75 mM
2-mercaptoethanol). Reactions were incubated for 10 min at 30 ◦C
and then stopped by boiling for 2 min. Tubes were then transferred
into watery ice and left to cool completely. Snake venom solution
(25 μl of 1 mg/ml) from Crotalus atrox was then added and the
tubes were incubated for 10 min at 30 ◦C. The tubes were then
returned to ice and 400 μl of pre-prepared Dowex®/water/ethanol
(1:1:1) slurry was added to each tube. The tubes were left on ice
for 15 min, with occasional vortex-mixing, and then centrifuged at
13000 g for 2 min at 4 ◦C in a refrigerated bench-top centrifuge.
A total of 150 μl of supernatant from the reaction tubes was
added to scintillation tubes containing 4 ml of scintillant, with
total counts being obtained by the addition of 50 μl of cAMP
substrate solution and then assayed in a scintillation counter.
Initial rates were taken from linear time courses of activity in all
experiments. The Km and Vmax determinations were performed
at substrate concentrations between 1 μM and 40 μM cAMP,
defined experimentally and confirmed by fitting to the hyperbolic
form of the Michaelis−Menten equation using GraphPad InStat
3. Dose-dependent inhibition by rolipram was determined in
the presence of 0.2 μM cAMP with rolipram at concentrations
between 0.01 nM and 1 mM.
Densitometry and statistical analysis
Non-saturating exposures from multiple experiments were quan-
tified densitometrically using ImageJ software. Densitometric
values for PDE4, the VSV tag and PKCα levels were normalized
to the expression of RACK1 protein levels in the same
sample. Statistical significance was determined using a two-tailed
Student’s t test or one-way ANOVA, where appropriate.
RESULTS
The effect of RACK1 on PDE4D5 subcellular localization
We have identified RACK1 protein as a cellular binding
partner for PDE4D5 previously [9]; however, the functional
importance of this interaction has yet to be determined. In
particular the role of RACK1 in the intracellular targeting
of PDE4D5 has yet to be investigated. To address this,
Table 1 Km, Vmax and IC50 values for PDE4D5-WT and PDE4D5-L33D
expressed in HEK-293 cells
Significant differences relative to pellet-associated PDE4D5-WT (*, ** and ***) or PDE4D5-L33D
(#, ## and ###) are indicated (P < 0.05, P < 0.01 and P < 0.001 respectively).
Transfection Fraction K m (μM) V max (pmol/min per mg) IC50 Rolipram (μM)
PDE4D5-WT Pellet 6.3 +− 0.9 0.32 +− 0.07 0.10 +− 0.01
PDE4D5-WT Soluble 16.7 +− 1.3** 9.71 +− 2.09**## 0.08 +− 0.02###
PDE4D5-L33D Pellet 20.0 +− 0.9*** 0.87 +− 0.09 10 +− 0.90***
PDE4D5-L33D Soluble 10.0 +− 1.5## 7.14 +− 1.62*# 0.09 +− 0.02###
HEK-293 cells were transfected with VSV-tagged cDNAs
encoding either wild-type PDE4D5 (PDE4D5-WT) or VSV-
tagged PDE4D5 where the leucine residue at position 33
in the unique N-terminus had been mutated to an aspartate
residue (PDE4D5-L33D). The L33D mutation in PDE4D5 has
been shown previously to prevent interaction with RACK1
[17] and immunoprecipitation experiments confirmed that this
was the case in HEK-293 cells (Supplementary Figure S1 at
http://www.BiochemJ.org/bj/432/bj4320207add.htm). Moreover,
immunoblotting and cAMP PDE assays of fractions demonstrated
that the relative distributions of PDE4D5-WT and PDE4D5-
L33D protein and activity were approximately equal between
the two fractions (Figure 1), whereas both PDE4D5-WT and
PDE4D5-L33D immunoreactivity was enriched in the cytosolic
fraction, with lower levels of expression in the particulate fractions
(Figure 1). Together these results suggest that association with
RACK1 does not play a significant role in determining the
subcellular distribution of PDE4D5 in HEK-293 cells.
Effect of interaction with RACK1 on the conformation of PDE4D5
Experiments were then carried out to determine the maximum
rate of catalysis (Vmax) of PDE4D5-WT or PDE4D5-L33D, and
the affinity of PDE4D5-WT or PDE4D5-L33D for cAMP (Km)
by using various concentrations of substrate (between 1 μM and
40 μM). Lineweaver−Burk plots of the results demonstrated
that Michaelis−Menten kinetics were being followed at each
of these substrate concentrations (Supplementary Figure S2
at http://www.BiochemJ.org/bj/432/bj4320207add.htm). The
Vmax values determined for the pellet fractions of both
PDE4D5-WT and PDE4D5-L33D were low, at 0.32 +− 0.07
and 0.87 +− 0.09 pmol/min per mg respectively, whereas the
supernatant fractions displayed higher rates of catalytic activity,
with PDE4D5-WT possessing a Vmax of 9.71 +− 2.09 pmol/min
per mg, greater than the PDE4D5-L33D Vmax value
of 7.14 +− 1.62 pmol/min per mg (Table 1). The higher rate of
catalysis observed in the supernatant fractions of PDE4D5-WT-
and PDE4D5-L33D-transfected HEK-293 cells agreed with
the relatively low Km values of 16.7 +− 1.3 and 10.0 +− 1.5 μM
respectively, indicating a fairly high affinity for cAMP. The pellet
fraction of PDE4D5-WT, however, showed a comparatively
lower Km value of 6.3 +− 0.9 μM, indicating a higher affinity
for its substrate (Table 1). Conversely, the non-RACK1-binding
PDE4D5-L33D mutant pellet fraction has a Km value of
20.0 +− 0.9 μM, demonstrating a loss of affinity for cAMP when
compared with the other PDE4D5 forms in the other fractions.
The significant difference in Km values indicates that the binding
of RACK1 to PDE4D5 in particulate fractions is essential for
maintaining the high affinity of PDE4D5 for cAMP in the
membrane fraction of cells. Next, we determined the effect
of RACK1 binding on the susceptibility of PDE4D5 to
a specific enzyme inhibitor by measuring the dose-response
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Figure 1 Distribution of PDE4D5-WT and PDE4D5-L33D activity and
immunoreactivity between soluble and particulate fractions of HEK-293 cells
Pellet (P2) and cytosol (S/N) fractions from HEK-293 cells transfected with cDNAs encoding
VSV-tagged wild-type PDE4D5 (PDE4D5-WT) or VSV-tagged PDE4D5-L33D (PDE4D5-L33D),
the non-RACK1-binding mutant, were immunoblotted with anti-RACK1 and anti-VSV antibodies.
Densitometric values were obtained from non-saturating immunoblots from three separate
experiments and plotted on the top histogram, to show the relative distributions of PDE4D5-WT
and PDE4D5-L33D between fractions. The middle histogram shows the relative distribution of
RACK1. PDE assays were also carried out on fractions from transfected cells and these are
displayed in the bottom histogram.
of PDE4D5-WT and PDE4D5-L33D to the PDE4 inhibitor
rolipram (at concentrations between 0.01 nM and 1 mM).
The responses of the soluble fraction PDE4D5-WT and
Figure 2 Dose−response curves of PDE4D5-WT and PDE4D5-L33D to
inhibition by rolipram
Particulate (P2) or soluble (S/N) fractions, prepared from HEK-293 cells transfected with cDNAs
encoding either PDE4D5-WT or PDE4D5-L33D, were treated with various concentrations of the
PDE4 inhibitor rolipram, ranging from 0 to 1 mM, and then assayed for PDE activity. PDE activities
obtained from three separate experiments were then plotted as means +− S.E.M. (1.E-03 =
1.0×10−1 etc.) PDE activities, in the absence of inhibitor, for PDE4D5-WT or PDE4D5-L33D
were 60 +− 10 pmol/min per mg, in the pellet fraction, and 550 +− 50 pmol/min per mg, in the
soluble fraction, respectively.
PDE4D5-L33D to inhibition by rolipram were very similar;
whereas the pellet fraction graph showed a clear difference
in the dose-responses of PDE4D5-WT and PDE4D5-L33D,
with PDE4D5-L33D being far less susceptible to inhibition
by rolipram (Figure 2). These results suggest that interaction
with RACK1 is important for maintaining the conformation of
PDE4D5 in the particulate fraction of HEK-293 cells. Together
these results (summarized in Table 1) suggest that PDE4D5
binding to RACK1 is necessary to enable high-affinity binding
of PDE4D5 to its substrate cAMP, and for effective inhibition by
rolipram in the particulate fraction of HEK-293 cells.
To test this idea further we carried out competition experiments
to attempt to disrupt the association of PDE4D5-WT with RACK1
in the particulate fraction of HEK-293 cells using RACK1-
derived peptides (500 μM). Pellet fractions were incubated
with 0.2 μM rolipram (Figure 3a; a concentration of rolipram
induced an approx. 40% inhibition of PDE4D5 in this fraction).
Rolipram inhibition was effectively ablated by RACK1-derived
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Figure 3 RACK1-derived peptides corresponding to the RACK1−PDE4D5
interaction interface block the inhibition of particulate PDE4D5 by rolipram
(a) Particulate fractions were prepared from HEK-293 cells that had been transfected with
PDE4D5-WT and PDE assays were carried out in the presence or absence of 0.1 μM rolipram
as described in the Materials and methods section. RACK1-derived peptides (corresponding
to amino acids 10−19, 35−48, 59−68, 99−108 and 272−283 of RACK1 as indicated) were
also included in PDE assays. Results are presented as the percentage inhibition of PDE4D5
activity and significant differences relative to samples treated with rolipram without peptide
(*P < 0.05), or with rolipram plus RACK1 peptide (59−68) (#P < 0.05), are indicated. PDE
activities, in the absence of inhibitor, for PDE4D5-WT or PDE4D5-L33D were 60 +− 10 pmol/min
per mg, in the pellet fraction, and 550 +− 50 pmol/min per mg, in the soluble fraction.
(b) RACK1-derived peptide array overlay experiments were carried out using purified,
recombinant GST−PDE4D5-WT as described in the Materials and methods section. Two
arrays of five overlapping peptides were prepared corresponding to the region of RACK1
that encompasses RACK1 peptides 35−48 and 99−108 respectively.
peptides corresponding to amino acids 35−48 and 99−108 of
RACK1 (Figure 3a). Peptides corresponding to amino acids
10−19, 59−68 and 272−283 of RACK1 had little effect on the
ability of 0.2 μM rolipram to inhibit PDE4D5 activity in this
fraction. These results suggest that part of the RACK1 interaction
interface with PDE4D5 is contributed by amino acids 35−48
and 99−108. To test this assumption peptide array experiments
were carried out using a range of immobilized peptides, which
span the region of RACK1 corresponding to amino acids 21−60
and 86−125, overlaid with purified recombinant PDE4D5-WT
(Figure 3b). PDE4D5-WT was found to interact most strongly
with immobilized peptides corresponding to amino acids 35−48
and 99−108 of RACK1 (Figure 3b). Together these results
support the idea that binding of PDE4D5 to amino acids
35−48 and 99−108 of particulate RACK1 is sufficient to evoke
conformational changes in PDE4D5 that is characterized by high-
affinity interaction with rolipram.
Figure 4 Enhanced PDE4 activity following stimulation of HEK-293 cells
with isoproterenol or PMA
HEK-293 cells were stimulated with 10 μM isoproterenol or 10 μM PMA for 15 min, and then
harvested and fractionated into high-speed pellet and supernatant fractions, and assayed for PDE
hydrolytic activity in the presence or absence of the PDE4 inhibitor rolipram (10μM) as described
in the Materials and methods section. Results obtained from three separate experiments were
normalized and plotted as means +− S.E.M. for each cellular fraction. Significant differences
relative to rolipram-treated samples are indicated (*P < 0.05).
PMA promotes PDE activation in the particulate, but not the soluble
fraction, of HEK-293 cells
Results so far suggest that RACK1 can sensitize PDE4D5 towards
interaction with cAMP and therefore may play a role in regulating
PDE4D5 activity. We therefore sought to determine the role
of the RACK1-interaction partner, PKC, on the activation of
PDE4 isoforms in HEK-293 cells. Cells were treated for 15 min
in the presence or absence of the β2-AR (β2-adrenoreceptor)
agonist 10 μM isoproterenol [18] or the PKC-activator PMA [19],
fractionated into high-speed pellet and cytosolic fractions, and
assessed for PDE activity in the presence or absence of the PDE4-
specific inhibitor rolipram, as described in the Materials and
methods section. Analysis of the total PDE activity in the pellet
fraction showed a significant increase in PDE activity following
isoproterenol or PMA stimulation, which was completely ablated
by inclusion of 10 μM rolipram in the assay (Figure 4). Analysis
of the supernatant fraction also demonstrated that isoproterenol
stimulated cell PDE4 activity, with an approx. 1.6-fold increase
when compared with non-stimulated cells (Figure 4). However, in
contrast with what was observed in the pellet fraction, PMA failed
to induce activation of PDE4 enzymes in the supernatant fraction
of HEK-293 cells. These results suggest that an increase in cAMP
levels following isoproterenol stimulation causes a significant
increase in PDE4 activity in soluble and particulate fractions of
HEK-293 cells; however, the action of PKC isoforms on PDE4
activity is limited to the pellet fraction in these cells.
RACK1 and PDE4D5 do not undergo activation-coupled
translocation in HEK-293 cells
The effects of PDE4D5 binding to RACK1 on the cellular
localization and activity of PDE4D5 has yet to be determined.
We therefore sought to determine whether translocation of
PDE4D5−RACK1, as reported previously for the PDE4D5−β-
arrestin signalling complex [20], contributed to the increases
in particulate PDE activity following isoproterenol stimulation
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Figure 5 RACK1 and PDE4D5 do not undergo activation-coupled
translocation following isoproterenol stimulation of HEK-293 cells
(a) Pellet and supernatant fractions from HEK-293 cells stimulated with 10 μM isoproterenol
at the indicated time points were immunoblotted with anti-PDE4D and anti-RACK1 antibodies.
RACK1 was enriched in the pellet fraction, whereas PDE4D5 and PDE4D3 (upper and lower
bands, 105 and 95 kDa respectively, of the doublet shown on the blot) are enriched in the
supernatant fraction. The immunoblots are representative of three separate experiments. (b)
HEK-293 cells were stimulated with 10 μM isoproterenol for the indicated times (between 0 and
60 min) and then immunoblotted with anti-CREB and anti-phospho-CREB (Ser133) antibodies.
Results are representative of three separate immunoblots.
(Figure 4). HEK-293 cells were stimulated for between 0
and 60 min with or without 10 μM isoproterenol and then
fractionated into particulate (pellet or P2) and cytosolic (soluble
or S/N) fractions. Immunoblotting fractions with antibodies
against PDE4D (recognizing all PDE4D isoforms) and RACK1
(Figure 5a) demonstrated that RACK1 immunoreactivity was
clearly enriched in the pellet fraction, whereas PDE4D3 and
PDE4D5 isoforms [4] were enriched in the supernatant fraction of
cells (Figure 5a). Stimulation with isoproterenol seemed to have
little effect on the distribution of PDE4D3, PDE4D5 or RACK1
between pellet and supernatant fractions at any of the time points
tested (Figure 5a); however, isoproterenol could stimulate the
phosphorylation of the PKA substrate CREB (cAMP-response-
element-binding protein) (Figure 5b), which is phosphorylated
in response to increased cAMP levels in a wide variety of cell
types [21]. These results indicate that isoproterenol is able to
stimulate elevations in intracellular cAMP levels in HEK-293
cells; however, RACK1−PDE4D5 does not appear to undergo
activation-coupled translocation in response to elevated levels of
intracellular cAMP in this cell type.
Effect of interaction with RACK1 on the activation of PDE4D5 by
isoproterenol and PKC isoforms
We next sought to investigate whether interaction with RACK1
has an effect on the ability of particulate PDE4D5 to be activated
by isoproterenol, which is a potent regulator of PDE4 activity
in HEK-293 cells (Figure 4). RACK1 was immunoprecipitated
from the pellet and soluble fractions of HEK-293 cells that
had been stimulated with 10 μM isoproterenol for 15 min
and PDE4D5 activity associated with the immunoprecipitates
was determined by PDE assay (Supplementary Figure
S3 at http://www.BiochemJ.org/bj/432/bj4320207add.htm). The
results demonstrated that isoproterenol stimulation provoked
a significant 1.6-fold increase in PDE4D5 activity associated
with RACK1 immunoprecipitates from solubilized particulate
fractions, but not from soluble fractions (Supplementary Figure
S3). This indicates that association with RACK1 causes a
conformational change in the PDE4D5 associated with the
particulate fractions, which enables PDE4D5 activation by
the cAMP signalling cascade.
Given that RACK1 is a scaffold protein for activated
conventional PKC isoforms [22], and that cAMP elevation has
recently been linked to the activation of PKC isoforms in a
number of different cell types [13], we next investigated whether
conventional PKC isoforms could be involved in mediating
the actions of isoproterenol on RACK1-bound PDE4D5. First,
we found that stimulation of cells with the PKC activator
PMA (10 μM) provoked similar levels of PDE4D5 activation
to isoproterenol in the particulate fraction, but not the soluble
fraction, of HEK-293 cells (Figure 4). HEK-293 cells were
next stimulated with either isoproterenol or PMA and then cells
were harvested and fractionated into particulate and soluble
fractions, which were then immunoprecipitated with anti-RACK1
antibodies (Figure 6). PKCα was clearly found to translocate
to the particulate fraction in response to PMA stimulation
(Supplementary Figure S4 at http://www.BiochemJ.org/bj/
432/bj4320207add.htm) indicating enzyme activation, as reported
previously [23], where it was also found to associate with
RACK1 as determined by immunoprecipitation (Figure 6a).
Surprisingly, isoproterenol stimulation also provoked an increase
in PKCα immunoreactivity in pellet fractions and in RACK1
immunoprecipitates from pellet fractions (Figure 6a), although
the degree of translocation elicited by isoproterenol was far
less than that produced by PMA. These results demonstrate
that isoproterenol stimulation provokes a significant activation
of RACK1-associated PKCα in the particulate fraction of HEK-
293 cells. This idea is supported by experiments showing that
isoproterenol stimulation is sufficient to provoke phosphorylation
of a large number of intracellular proteins in HEK-293 cells
in a PKC-dependent manner (Supplementary Figure S5 at
http://www.BiochemJ.org/bj/432/bj4320207add.htm). Moreover,
we also found that stimulation of HEK-293 cells with either
isoproterenol or PMA provoked a robust phosphorylation of
Ser126 of RACK1-associated PDE4D5, which was blocked by
co-incubation with the general PKC inhibitor GFX (Figure 6b).
Given that phosphorylation of Ser126 has been shown to be vital
for PDE4D5 activation in response to elevations in intracellular
cAMP [24], the cAMP- and PKC-dependent phosphorylation of
this site provides a potential mechanism for the activation
of RACK1-bound PDE4D5 in HEK-293 cells.
The identification of a stable interaction between RACK1 and
PKCα, and the subsequent phosphorylation of Ser126 of PDE4D5
leads to the question as to whether the interaction between PKCα
and RACK1 has any effect on RACK1-bound PDE4D5 activity in
the particulate fraction of HEK-293 cells. Our results from PDE
assays carried out on RACK1 immunoprecipitates suggest that
this might be the case (Supplementary Figure S3). To test this
further we examined the PDE activity associated with RACK1
immunoprecipitated from cells that had been stimulated with
either isoproterenol or PMA, in the presence or absence of the
PKA inhibitor H-89 or the PKC inhibitor GFX (Figure 7a). Both
isoproterenol and PMA were found to provoke a robust activation
of RACK1-associated PDE activity, which was completely
ablated by co-incubation with GFX (Figure 7a), indicating
that the stimulation of PDE activity by both agents requires
PKC. In contrast, co-incubation with H-89 only inhibited the
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Figure 6 PMA or isoproterenol stimulation promotes the association of PKCα with RACK1 and promotes PKC-dependent phosphorylation of PDE4D5 on
Ser126 in the particulate fraction of HEK-293 cells
(a) Soluble (S/N) or particulate (pellet) fractions from HEK-293 cells were stimulated with diluent (DMSO), isoproterenol or PMA for 15 min, and then immunoprecipitated with either mouse IgM
(negative control) or anti-RACK1 antibody (IgM clone), and immunoblotted with anti-RACK1 and anti-PKCα antibodies. Densitometric values from the RACK1-immunoprecipitated samples were
plotted as means +− S.E.M. for three separate experiments and the results are shown in the lower panel as the fold change in PKCα interaction with RACK1 in each fraction. Significant increases
in PKCα immunoreactivity are indicated (*P < 0.05 and **P < 0.01). (b) HEK-293 cells were stimulated with diluent (DMSO), isoproterenol or PMA for 15 min in the presence or absence of the
general PKC inhibitor, GFX (10 μM), or the PP2A inhibitor okadaic acid (10 μM). RACK1 immunoprecipitates were then immunoblotted with specific antisera against pan-PDE4D, RACK1 and
phospho-PDE4D, which recognizes phosphorylated Ser126 of PDE4D5 (upper band) and PDE4D3 (lower band).
isoproterenol-stimulated PDE activity (Figure 7a). This indicates
that part of the action of isoproterenol on RACK1-associated PDE
activity requires PKA, as well as PKC, as previously reported [24].
We also found that our RACK1 immunoprecipitates from PMA-
stimulated cells contained significant amounts of activated ERK
(extracellular-signal-regulated kinase) (Figure 7b). Therefore to
demonstrate that it is PKC activation in itself, and not the action of
the downstream PKC-effector pathway, i.e. the Raf/ERK cascade
[25], that is responsible for the activation of PDE4D5 in the
particulate fraction of HEK-293 cells, cells were treated with
general PKC inhibitors and the inhibitor of the Raf substrate
MEK [MAPK (mitogen-activated protein kinase)/ERK kinase]
[25], and PDE activity levels were determined (Figure 7c). HEK-
293 cells were pre-treated with U0126, a specific inhibitor of
MEK1 and 2, a known downstream effector of PKC signalling
[25], or with the PKC specific inhibitors Ro-31-7549 or GFX
for 30 min, then stimulated for 15 min with or without PMA.
Immunoblots of cell lysates demonstrated a robust activation
of the MEK substrate ERK following PMA stimulation, which
is completely ablated following U0126, Ro-31-7549 or GFX
treatment (Figure 7c). In contrast, treatment with U0126 failed to
block particulate PDE4D5 activation following PMA stimulation,
whereas treatment of PMA-stimulated cells with Ro-31-7549 and
GFX caused a significant reduction in PDE activity (Figure 7d).
These results show that activation of PDE4D5 by PMA-stimulated
PKC isoforms is through a direct effect of PKC on PDE4D5 and
not through activation of the downstream effector MEK.
Finally, to test whether interaction with RACK1 is required
for activation of particulate PDE4D5 by PKC, the effect of PMA
was tested on HEK-293 cells transfected with PDE4D5-WT or
the PDE4D5-L33D RACK1-binding mutant. Transfected cells
were stimulated in the presence or absence of PMA for 15 min,
before being harvested, fractionated and the PDE4D5 activity
in fractions assayed by PDE assay. The results demonstrated an
almost 3.5-fold increase in PDE4D5 activity in the pellet fraction
from PDE4D5-WT-transfected cells stimulated with PMA, in
comparison with the non-stimulated PDE4D5-WT pellet fraction
(Figure 8a). In contrast, the pellet fraction from PMA-stimulated
PDE4D5-L33D cells shows a PDE activity change of only
approx. 1.5-fold (Figure 8a). These results show that interaction
with RACK1 in the particulate fraction of HEK-293 cells is
required for PKC to be able to efficiently activate PDE4D5. To
confirm that interaction with RACK1 is required for effective
activation of RACK1-associated PDE4D5, we took advantage
of cell-permeant peptide inhibitors of the interaction between
PDE4D5 and RACK1, compared with an additional peptide that
disrupts the interaction between PDE4D5 and β-arrestin [11,26].
We found that disruption of the PDE4D5−RACK1 interaction
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Figure 7 Activation of RACK1-associated PDE4D5 by PMA or isoproterenol requires PKC, but not ERK
(a) HEK-293 cells were stimulated for 15 min with either 10 μM PMA or 10 μM isoproterenol, in the presence or absence of the PKA inhibitor H-89 (10 μM) or GFX (10 μM). RACK1 was then
immunoprecipitated from cells and associated PDE activities were determined as described in the Materials and methods section. Results represent means +− S.E.M. for three separate experiments.
Significant differences relative to cells stimulated with isoproterenol or PMA alone are indicated (***P < 0.001 and ###P < 0.001). (b) RACK1 immunoprecipitates from cells stimulated with either
10 μM PMA or 10 μM isoproterenol, in the presence or absence of GFX (10 μM) or okadaic acid (10 μM), were immunoblotted with anti-phospho-ERK or anti-total-ERK antibodies. Results are a
representative immunoblot from an experiment carried out on three separate occasions with similar results. (c) HEK293 cells were transfected with cDNA encoding PDE4D5-WT and then pre-treated
for 30 min with either diluent (DMSO) or inhibitor (U0126, Ro-31-7549 or GFX) and then stimulated with or without PMA for 15 min. Lysates were then immunoblotted with anti-total-ERK and
anti-phospho-ERK antibodies. Results represent a single experiment carried out on three separate occasions with similar results. (d) PDE4D5-WT-transfected cells were pre-treated with U0126,
Ro-31-7549 or GFX prior to 15 min of PMA stimulation. Cells were then fractionated and PDE4D5 activity associated with the particulate fraction of cells was assessed with the PDE assay. Results are
expressed as a percentage of the maximum (PMA-treated cells) and are means +− S.E.M. for three separate experiments. Significant differences relative to PMA-treated cells are indicated (**P < 0.01).
caused a significant reduction in PDE activity in PDE4D5-
specific immunoprecipitates from isoproterenol-stimulated
HEK-293 cells, whereas disruption of the PDE4D5−β-arrestin
interaction had little effect on isoproterenol-stimulated PDE4D5
activity (Figure 8b).
DISCUSSION
To fully appreciate the pleiotropic actions of cAMP in cells
the role of specific cAMP PDEs, their interaction with cellular
proteins and the effects of this interaction on PDE activity must
be determined. Progress is starting to be made in this direction,
particularly in the characterization of protein interactions with
the cAMP-specific PDE4D5 and the scaffold protein β-arrestin
[27−29]. This complex is recruited from the cytosol to the
plasma membrane, in response to activation of the β2-AR, to
specifically hydrolyse cAMP in the vicinity of the β2-AR [20,28].
In the present study we found that isoproterenol stimulation
was sufficient to elevate cAMP and activate PDE4 activity in
general in HEK-293 cells (Figure 4), and PDE4D5 specifically
associated with RACK1 in the particulate fraction of cells
(Figure 7a); however, we did not see any translocation of the
RACK1−PDE4D5 complex (Figure 5a). This is perhaps not
surprising since the β-arrestin−PDE4D5 translocation seems to
occur in cells that express β2-AR to a very high level, e.g.
in cardiomyocytes [30] or HEK-293 cells stably transfected to
express high levels of receptor [20,30], and may reflect the
ability of β-arrestin to develop high-affinity interactions with this
receptor type. Indeed, little translocation of β-arrestin−PDE4D5
is seen in wild-type HEK-293 cells, with no overexpression of the
β2-AR (G. Baillie, unpublished work). The β2-AR may therefore
present an effective recruitment site for β-arrestin−PDE4D5
signalling complexes, but not for RACK1−PDE4D5 complexes.
It therefore remains to be determined what structural influences
direct the recruitment of RACK1−PDE4D5 complexes to the
particulate fraction of cells.
We found that RACK1 binding exerted a conformational change
in PDE4D5 in the particulate fraction of cells (Table 1), which
sensitizes PDE4D5 towards cAMP, perhaps priming PDE4D5 for
activation in this fraction. Rolipram also interacts with the active-
site of PDE4D5 [31] and dose−response experiments revealed
that particulate PDE4D5 was more susceptible to inhibition by
rolipram if bound to RACK1 (Figures 2 and 3). Rolipram is a
drug that has the potential to treat a variety of diseases, ranging
from depression to Alzheimer’s disease [32], but has a number of
side effects, including an emetic effect [33]. The implication that
RACK1 binding to PDE4D5 lowers the effective concentration
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Figure 8 Association with RACK1 is required for PDE4D5 to be activated by
PMA in the particulate fraction of HEK-293 cells
(a) Particulate (pellet) and soluble (S/N) fractions from HEK-293 cells transfected with either
PDE4D5-WT or PDE4D5-L33D and then stimulated with either diluent (DMSO) or PMA for
15 min were assayed for PDE activity. Significant differences relative to control are indicated;
**P < 0.01 (n = 3). PDE activities for PDE4D5-WT or PDE4D5-L33D prior to treatment were
60 +− 10 pmol/min per mg, in the pellet fraction, and 550 +− 50 pmol/min per mg, in the
soluble fraction. (b) HEK-293 cells were stimulated with diluent or 10 μM isoproterenol
in the presence or absence of cell-permeant inhibitory peptides that disrupt the interaction
between PDE4D5 and RACK1, or PDE4D5 and β-arrestin, as indicated. Cell extracts were
prepared and immunoprecipitated with an antibody against for PDE4D5. Immunoprecipitates
were then assayed for PDE activity. Results are means +− S.E.M. for three separate experiments
and significant differences relative to unstimulated cells or cells stimulated with isoproterenol
alone are indicated (**P < 0.01; ***P < 0.001; #P < 0.05).
of rolipram, provides the possibility of RACK1-derived peptides
(such as amino acids 35−48 and 99−108 in Figure 3), or synthetic
analogues, being taken therapeutically to potentially lessen these
side effects.
The present study also highlights the potential for direct
phosphorylation and activation of RACK1-bound PDE4D5 by
PKCα; however, there have been no previous published reports
demonstrating that PDE4D5 is a PKC substrate. Two mechanisms
have been suggested by which PMA treatment leads to PDE4D5
activation. The first involves activation of an ERK-controlled
autocrine loop [24]; however, this mechanism is unlikely to
account for the rapid ERK-independent activation of RACK1-
associated PDE4D5 seen in the present study. The second
mechanism involves inactivation of the RACK1-binding partner
[34,35] PP2A (protein phosphatase 2A) by PKC, leading to an
increase in the phosphorylation of stimulatory Ser126 on PDE4D5
[36]. In the present study we did find that both isoproterenol
and PMA provoked a rapid PKC-dependent phosphorylation
of RACK1-associated PDE4D5 on Ser126 (Figure 5b); however,
the PP2A inhibitor okadaic acid had little effect on Ser126
phosphorylation (Figure 6b), although it did enhance intracellular
phosphorylation of PKC substrates in response to both of these
agents (Supplementary Figure S5). It therefore remains to be
determined whether PP2A is in fact a PKC-controlled regulator
of RACK1-associated PDE4D5.
Altogether, the results of the present study demonstrate that
the complex formed between PDE4D5 and RACK1 provides a
novel point of cross-talk between the cAMP and PKC signalling
pathways, providing a potential point of negative feedback in
the cAMP signalling cascade. This potential has come to light
given recent findings that increased cAMP levels activate PKC
[13], which we confirm in the present study (Figure 6a and
Supplementary Figure S5). Therefore if PKC activation increases
PDE activity, as we demonstrate in the present study, this has the
potential to reduce cellular cAMP levels and, in turn, limit PKC
activation.
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Interaction with receptor for activated C-kinase 1 (RACK 1) sensitizes the
phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation
by protein kinase C
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Figure S1 Wild-type PDE4D5, but not PDE4D5-L33D, associates with
RACK1 in HEK-293 cells
Confluent HEK-293 cells were transiently transfected with VSV-tagged PDE4D5 wild-type
(PDE4D5-WT) or VSV-tagged PDE4D5-L33D mutant (PDE4D5-L33D). Whole-cell lysates were
then prepared and immunoprecipitated (I.P.) with control (IgM) antibody or anti-RACK1 antibody
(IgM clone). Immunoprecipitates were then immunoblotted with anti-VSV antibodies, to detect
PDE4D5 forms, or anti-RACK1 antibody. Results are representative of an experiment carried out
on three separate occasions.
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Figure S2 Lineweaver−Burk plots for PDE4D5-WT and PDE4D5-L33D
Particulate (pellet; upper panel) and soluble fractions (S/N; lower panel) from HEK-293 cells
were transfected with cDNAs encoding PDE4D5-WT or PDE4D5-L33D and assayed for PDE
activity in the presence of cAMP at concentrations between 1 μM and 40 μM. Mean PDE activ-
ities from three separate experiments were then used to produce Lineweaver−Burk plots for
each fraction.
Figure S3 Isoproterenol and PMA stimulate PDE4 activity associated with
RACK1 immunoprecipitates from HEK-293 cells
Confluent HEK-293 cells were stimulated with either 10 μM isoproterenol or 10 μM PMA
and then fractionated into soluble (S/N) and particulate (pellet) fractions, which were then
immunoprecipitated with anti-RACK1 antibodies. RACK1 immunoprecipitates were then assayed
for associated PDE activity in the presence or absence of rolipram, as indicated. The results
are means +− S.E.M. for three separate experiments and are plotted as the fold change relative
to non-stimulated cells (DMSO). Significant differences relative to the control are indicated
(*P< 0.01).
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Activation of PDE4D5 by PKC requires interactions with RACK1
Figure S4 Stimulation of HEK-293 cells with PMA triggers intracellular
translocation of PKCα, but not RACK1
HEK-293 cells were stimulated with 10 μM PMA for between 0 and 60 min, following which
cells were fractionated into soluble (S/N) and particulate (pellet) fractions then immunoblotted
with anti-RACK1 and anti-PKCα antibodies. The immunoblots show that PKCα translocates
from the supernatant to the pellet fraction within 5 min of PMA stimulation. Densitometry
was carried out on non-saturated immunoblots from three separate experiments and plotted
as means +− S.E.M. Significant differences relative to non-stimulated control are indicated
(*P< 0.05 and **P< 0.01).
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Figure S5 Stimulation of HEK-293 with ispoproterenol provokes serine
phosphorylation of multiple intracellular proteins in a PKC-dependent
manner
HEK-293 cells were stimulated for 15 min with either 10 μM isoproterenol or 10 μM PMA
in the presence or absence of 10 μM GFX or 10 μM okadaic acid, as indicated. Cell lysates
were then immunoblotted with an anti-PKC substrate phospho-specific antibody. The arrows
on the right-hand side indicate immunoreactive protein species phosphorylated in response to
isoproterenol that were both inhibited by GFX and enhanced by okadaic acid.
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